New lipid modulating drugs: The role of microsomal transport protein inhibitors

Current Pharmaceutical Design

Volumn 17, Issue 9, 2011, Pages 943-949

  Rizzo, Manfredi ^a   Wierzbicki, Anthony S ^b  

^a UNIVERSITY OF PALERMO   (Italy)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Atherosclerosis; Cardiovascular prevention; Lipids; Lipoproteins; MTP inhibitors

Indexed keywords

AMINOTRANSFERASE; APOLIPOPROTEIN B; ATORVASTATIN; BAY 139953; BEZAFIBRATE; CP 346086; EZETIMIBE; FENOFIBRATE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMPLITAPIDE; JTT 130; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR; SLX 4090; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ABSENCE OF SIDE EFFECTS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG FORMULATION; DRUG RESPONSE; DRUG WITHDRAWAL; FAMILIAL HYPERCHOLESTEROLEMIA; FATTY LIVER; FLATULENCE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRANSAMINASEMIA; HYPERTRIGLYCERIDEMIA; LIVER FATTY DEGENERATION; LOOSE FECES; LOW DRUG DOSE; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; SIDE EFFECT; SINGLE DRUG DOSE;

ABETALIPOPROTEINEMIA; APOLIPOPROTEINS B; CARRIER PROTEINS; HUMANS; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA TYPE II; HYPERTRIGLYCERIDEMIA; LIPOPROTEINS, VLDL; MICROSOMES;

EID: 79958222144     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211795428768     Document Type: Article

References (76)

1. Stein EA. Management of dyslipidemia in the high-risk patient. Am Heart J 2002; 144: S43-50
2. Expert Panel on Detection, Evaluation, and Treatment of HighBlood Cholesterol in Adults. Executive Summary of the Third Reportof the National Cholesterol Education Program (NCEP) ExpertPanel on Detection, Evaluation, and Treatment of High Blood Cho-lesterolin Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-97.
3. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recentclinical trials for the National Cholesterol Education Program AdultTreatment Panel III Guidelines. Circulation 2004; 110: 227-39.
4. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guidelinefor assessment of cardiovascular risk in asymptomatic adults: executive summary: a report of the American College of Cardiology-Foundation/American Heart Association Task Force on Practice-Guidelines. J Am Coll Cardiol 2010; 56: 2182-99.
5. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guidelinefor assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.Circulation 2010; 122: e584-636.
6. Fruchart JC, Sacks F, Hermans MP, et al. The Residual Risk ReductionInitiative: a call to action to reduce residual vascular risk inpatients with dyslipidemia. Am J Cardiol 2008; 102 (10 Suppl):1K-34K.
7. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Atherosclerosis 2007; 194: 1-45.
8. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invitedexperts). Eur J Cardiovasc Prev Rehabil 2007; 14 Suppl 2:S1-113.
9. British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, The Stroke Association. JBS 2: the Joint British Societies' guidelines for prevention of cardiovascular disease in clinical practice. Heart 2005; 91(suppl V): v1-v52.
10. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the riskof coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007;115: 450-8.
11. Austin MA. Triglyceride, small, dense low-density lipoprotein, andthe atherogenic lipoprotein phenotype. Curr Atheroscler Rep 2000;2: 200-7.
12. St-Pierre AC, Cantin B, Dagenais GR, et al. Low-density lipopro-teinsubfractions and the long-term risk of ischemic heart disease inmen: 13-year follow-up data from the Quebec CardiovascularStudy. Arterioscler Thromb Vasc Biol 2005; 25: 553-9.
13. Rizzo M, Berneis K. Lipid triad or atherogenic lipoprotein phenotype:a role in cardiovascular prevention? J Atheroscler Thromb 2005; 12: 237-9.
14. Eckel RH, Alberti KG, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2010; 375: 181-3.
15. Jungner I, Sniderman AD, Furberg C, Aastveit AH, Holme I, Walldius G. Does low-density lipoprotein size add to atherogenic particle number in predicting the risk of fatal myocardial infarction? Am J Cardiol 2006; 97: 943-6.
16. Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipopro-teins,and risk of vascular disease. JAMA 2009; 302: 1993-2000.
17. Gazi IF, Tsimihodimos V, Tselepis AD, Elisaf M, Mikhailidis DP.Clinical importance and therapeutic modulation of small denselow-density lipoprotein particles. Expert Opin Biol Ther 2007; 7:53-72.
18. Packard CJ. Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease. Curr Opin Lipidol 2006; 17: 412-7.
19. Rizzo M, Berneis K. Low-density-lipoproteins size and cardiovas-cularrisk assessment QJM - Int J Med 2006; 99: 1-14.
20. Otvos JD, Collins D, Freedman DS, et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006; 113: 1556-63.
21. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res 1982; 23: 97-104.
22. Berneis KK, Krauss RM. Metabolic origins and clinical signific-anceof LDL heterogeneity. J Lipid Res 2002; 43: 1363-79.
23. Rizzo M, Berneis K. Should we measure routinely the LDL peak particle size? Int J Card 2006; 107: 166-70.
24. Cromwell WC, Otvos JD. Low-density lipoprotein particle number and risk for cardiovascular disease. Curr Atheroscler Rep 2004; 6:381-7.
25. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia in-creasesendothelial superoxide anion production. J Clin Invest 1993; 91: 2546-51.
26. Rizzo M, Kotur-Stevuljevic J, Berneis K, et al. Atherogenic dyslip-idemiaand oxidative stress: a new look. Transl Res 2009; 153:217-23.
27. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-95.
28. Galeano NF, Al-Haideri M, Keyserman F, Rumsey SC, Deckelbaum RJ. Small dense low density lipoprotein has increased affin-ityfor LDL receptor-independent cell surface binding sites: a po-tentialmechanism for increased atherogenicity. J Lipid Res 1998;39: 1263-73.
29. Tribble DL, Krauss RM, Lamberg MG, Thiel PM, van den Berg JM. Greater oxidative susceptibility of the surface monolayer in small dense LDL may contribute to differences in copper-induced oxidation among LDL density subfractions. J Lipid Res 1995; 36:662-71.
30. Tribble DL, Rizzo M, Chait A, Lewis DM, Blanche PJ, Krauss RM. Enhanced oxidative susceptibility and reduced antioxidantcontent of metabolic precursors of small, dense low-density lipo-proteins. Am J Med 2001; 110: 103-10.
31. Matsuura E, Hughes GR, Khamashta MA. Oxidation of LDL and its clinical implication. Autoimmun Rev 2008; 7: 558-66.
32. Vekic J, Kotur-Stevuljevic J, Jelic-Ivanovic Z, et al. Association ofoxidative stress and PON1 with LDL and HDL particle size inmiddle-aged subjects. Eur J Clin Invest 2007; 37: 715-23.
33. Vekic J, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V, Memon L, et al. High serum uric acid and low-grade inflammation are associatedwith smaller LDL and HDL particles. Atherosclerosis 2009;203: 236-42.
34. Murdoch SJ, Breckenridge WC. Influence of lipoprotein lipase and hepatic lipase on the transformation of VLDL and HDL during lipolysis of VLDL. Atherosclerosis 1995; 118: 193-212.
35. Nicoll A, Lewis B. Evaluation of the roles of lipoprotein lipase and hepatic lipase in lipoprotein metabolism: in vivo and in vitro studies in man. Eur J Clin Invest 1980; 10: 487-95.
36. Campos H, Dreon DM, Krauss RM. Associations of hepatic and lipoprotein lipase activities with changes in dietary composition and low density lipoprotein subclasses. J Lipid Res 1995; 36: 462-72,
37. Rizzo M, Taylor JM, Barbagallo CM, Berneis K, Blanche PJ, Krauss RM. Effects on lipoprotein subclasses of combined expression of human hepatic lipase and human apo B in transgenic rabbits. Arterioscler Thromb Vasc Biol 2004; 24: 141-6,
38. Deckelbaum RJ, Granot E, Oschry Y, Rose L, Eisenberg S. Plasma triglyceride determines structure-composition in low and high den-sitylipoproteins. Arteriosclerosis 1984; 4: 225-31.,
39. Guerin M, Le Goff W, Lassel TS, Van Tol A, Steiner G, Chapman MJ. Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes: impact of the degree of triglyceridemia. Arterioscler Thromb Vasc Biol 2001; 21: 282-8.
40. Wierzbicki AS, Mikhailidis DP, Wray R, et al. Statin-fibrate com-binationtherapy for hyperlipidaemia: A review. Curr Med ResOpin 2003; 19: 155-68.
41. Wierzbicki AS. Fibrates: no ACCORD on their use in the treatment of dyslipidaemia. Curr Opin Lipidol 2010; 21: 352-8.
42. Rizzo M, Berneis K. The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates.Curr Med Res Opin 2007; 23: 1103-11.
43. Rizzo M, Berneis K. The clinical relevance of low-density-lipoproteinssize modulation by statins. Cardiovasc Drugs Ther 2006; 20: 205-17.
44. Rizzo M, Berneis K, Spinas GA, Rini GB, Kapur NK. Quantitative and qualitative effects of rosuvastatin on LDL-cholesterol: what is the clinical significance? Int J Clin Pract 2009; 63: 478-85.
45. Mikhailidis DP, Wierzbicki AS, Daskalopoulou SS, et al. The useof ezetimibe in achieving low density lipoprotein lowering goals inclinical practice: Position statement of a United Kingdom consen-suspanel. Curr Med Res Opin 2005; 21: 959-69.
46. Rizzo M, Rini GB, Spinas GA, Berneis K. The effects of ezetimibe on LDL-cholesterol: quantitative or qualitative changes? Atherosclerosis 2009; 204: 330-3.
47. Berneis K, Rizzo M, Berthold HK, Spinas GA, Krone W, Gouni-Berthold I. Ezetimibe alone or in combination with simvastatin in-creasessmall, dense low-density lipoproteins in healthy men: a randomized trial. Eur Heart J 2010; 31: 1633-9.
48. Florentin M, Liberopoulos EN, Moutzouri E, Rizos CV, Tselepis AD, Elisaf MS. The effect of simvastatin alone versus simvastatinplus ezetimibe on the concentration of small dense low-densitylipoprotein cholesterol in subjects with primary hypercholesterolemia.Curr Med Res Opin 2011; 27: 685-92.
49. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Ezetimibe and low density lipoprotein subfractions: an ongoing debate. Curr Med Res Opin 2011; 27: 693-5.
50. Wierzbicki AS, Hardman T, Prince WT. Future challenges for mi-crosomaltransport protein inhibitors. Curr Vasc Pharmacol 2009;7: 277-86.
51. Rutledge AC, Qiu W, Zhang R, Kohen-Avramoglu R, Nemat-Gorgani N, Adeli K. Mechanisms targeting apolipoprotein B100 to proteasomal degradation: evidence that degradation is initiated by BiP binding at the N terminus and the formation of a p97 complex at the C terminus. Arterioscler Thromb Vasc Biol 2009; 29: 579-85.
52. Gordon DA, Jamil H. Progress towards understanding the role of microsomal triglyceride transfer protein in apolipoprotein- B lipoproteinassembly. Biochim Biophys Acta 2000; 1486: 72-83.
53. Rader DJ, Brewer HB. Abetalipoproteinemia. New insights into lipoprotein assembly and vitamin E metabolism from a rare geneticdisease. JAMA 1993; 270: 865-9.
54. Sharp D, Ricci B, Kienzle B, Lin MC, Wetterau JR. Human micro-somaltriglyceride transfer protein large subunit gene structure. Biochemistry 1994; 33: 9057-61.
55. Sharp D, Blinderman L, Combs KA, et al. Cloning and gene de-fectsin microsomal triglyceride transfer protein associated withabetalipoproteinaemia. Nature 1993; 365: 65-9.
56. Wetterau JR, Gregg RE, Harrity TW, et al. An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science 1998; 282: 751-4.
57. Shoulders CC, Shelness GS. Current biology of MTP: implications for selective inhibition. Curr Top Med Chem 2005; 5: 283-300.
58. Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microso-maltriglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 2007; 356: 148-56.
59. Robl JA, Sulsky R, Sun CQ, et al. A Novel Series of Highly Potent Benzimidazole-Based Microsomal Triglyceride Transfer Protein Inhibitors. Journal of Medicinal Chemistry 2001; 44: 851-6.
60. Funatsu T, Kakuta H, Takasu T, Miyata K. Atorvastatin increaseshepatic fatty acid beta-oxidation in sucrose-fed rats: comparison with an MTP inhibitor. Eur J Pharmacol 2002; 455: 161-7.
61. Chandler CE, Wilder DE, Pettini JL, et al. CP-346086: an MTPinhibitor that lowers plasma cholesterol and triglycerides in ex-perimentalanimals and in humans. J Lipid Res 2003; 44: 1887-901
62. Ellis J, Bartolozzi A, Ferkany J, et al. SLx-4090, an Enterocyte Specific Micorsomal Triglyceride Transport Protein (MTP) Inhibi-torLowers LDL Cholesterol and Triglycerides While Raising HDL Cholesterol in Apo E-/- Mice Fed a High Fat Diet. ArteriosclerThromb Vasc Biol 2007; 27: e64.
63. Ueshima K, Kihisa-Umeno H, Nagayoshi A, Takakura S, Matsuo M, Mutoh S. Implitapide, a microsomal triglyceride transfer proteininhibitor, reduces progression of atherosclerosis in apolipoprotein Eknockout mice fed a Western-type diet: involvement of the inhibitionof postprandial triglyceride elevation. Biol Pharm Bull 2005;28: 247-52.
64. Aggarwal D, West KL, Zern TL, Shrestha S, Vergara-Jimenez M,Fernandez ML. JTT-130, a microsomal triglyceride transfer protein(MTP) inhibitor lowers plasma triglycerides and LDL cholesterolconcentrations without increasing hepatic triglycerides in guineapigs. BMC Cardiovasc Disord 2005; 5: 30.
65. Prince WT, Warwick Tong E, Andersen G, et al. SLx-4090: Firsthuman experience and proof of concept for an enterocyte-specificmicrosomal triglyceride transfer protein inhibitor. Circulation.2006; 114: 2427.
66. Prince WJ, Tong W, Frekany J, Andersen G. SLX-4090- repeatdose treatment with a novel enterocyte specific MTP inhibitor re-ducespost-prandial triglyceride response and lowers LDL-C inhealthy volunteers. J Clin Lipidol 2007; 1: 471.
67. Farnier M, Stein E, Megnien S, et al. Efficacy and safety of impli-tapide,a microsomal triglyceride protein inhibitor in patients with primary hypercholesterolemia. XIV International Symposium onDrugs Affecting Lipid Metabolism 2001. New York: GiovanniLorenzini Medical Foundation; 2001: 46.
68. Samaha FF, McKenney J, Bloedon LT, Sasiela WJ, Rader DJ. In-hibitionof microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat ClinPract Cardiovasc Med 2008; 5: 497-505.
69. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase IIClinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism(DALM) 2007 Conference. Aegerion Pharmaceuticals Inc Press Release 2007.
70. Rizzo M. Lomitapide, a microsomal triglyceride transfer protein inhibitor for the treatment of hypercholesterolemia. IDrugs 2010;13: 103-11.
71. Cuchel M, Meagher E, Marais AD, et al. Abstract 1077: A phaseIII study of microsomal triglyceride transfer protein inhibitor lomitapide(AEGR-733) in patients with homozygous familial hypercholesterolemia:interim results at 6 months. Circulation 2009; 120:S441.
72. Chan DC, Watts GF, Gan SK, Ooi EM, Barrett PH. Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight lossdiet. Diabetes Care 2010; 33: 1134-9.
73. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E.High apolipoprotein B, low apolipoprotein A-I, and improvementin the prediction of fatal myocardial infarction (AMORIS study): aprospective study. Lancet 2001; 358: 2026-33.
74. Sniderman AD, Jungner I, Holme I, Aastveit A, Walldius G. Errorsthat result from using the TC/HDL C ratio rather than theapoB/apoA-I ratio to identify the lipoprotein-related risk of vascu-lardisease. J Intern Med 2006; 259: 455-61.
75. Barter PJ, Ballantyne CM, Carmena, et al. Apo B versus choles-terolin estimating cardiovascular risk and in guiding therapy: re-portof the thirty-person/ten-country panel. J Intern Med 2006; 259:247-58.
76. Holme I, Aastveit AH, Jungner I, Walldius G. Relationships be-tweenlipoprotein components and risk of myocardial infarction:age, gender and short versus longer follow-up periods in the Apol-ipoproteinMOrtality RISk study (AMORIS). Intern Med 2008;264: 30-8.